CFB
SUPN icon

Cullen/Frost Bankers’s Supernus Pharmaceuticals SUPN Stock Holding History

Cullen/Frost Bankers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28
Closed -$1.45K – 1485
2026
Q1 		$1.45K Sell
28
-390
-93% -$19.9K ﹤0.01% 1285
2025
Q4 		$20.8K Buy
+418
New +$20.3K ﹤0.01% 994
2022
Q2 		– Sell
-11
Closed – – 1188
2022
Q1 		$0 Hold
11
– – ﹤0.01% 1246
2021
Q4 		$0 Buy
+11
New +$334 ﹤0.01% 1319

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Cullen/Frost Bankers's SUPN Position: Q2 2026 in Review

Cullen/Frost Bankers sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 28 shares — an estimated $1.45K sold.

Cullen/Frost Bankers first reported a position in SUPN in Q4 2021 and held it in 4 quarters. The position peaked at $20.8K in Q4 2025. 131 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Cullen/Frost Bankers reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cullen/Frost Bankers sold 28 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.45K.
  • Cullen/Frost Bankers first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Cullen/Frost Bankers's Supernus Pharmaceuticals position peaked at $20.8K in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.